Internal Medicine, Hematology & Oncology · Fort Worth, TX
NPI
1063415735
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1307 8th Ave, Suite 205
Fort Worth, TX, 76104
Phone (817) 924-4300
Groups this clinician bills Medicare through
Medicare paid, 2024
$610K
98,701 services
Medicare patients, 2024
517
Average age 75
Drug cost, 2024
$2.9M
1,644 prescriptions
Company payments, 2025
$3,403
From 42 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mary Milam was code 85025 (blood count), 1,241 times for 439 patients. In total Mary Milam billed 98,701 services in 110 codes, and Medicare paid $610K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-07-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 85025 Blood Count | Office | 1,241 | 439 | $7.60 | $9,436 |
| 36415 Venipuncture Blood Collection | Office | 1,145 | 427 | $8.65 | $9,904 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,044 | 11 | $0.08 | $78.5 |
| 99213 Office E&M - Established | Office | 906 | 279 | $67.31 | $61K |
| 80053 Clinical Chemistry | Office | 788 | 382 | $10.34 | $8,147 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 504 | 305 | $12.78 | $6,441 |
| 99214 Office E&M - Established | Office | 502 | 300 | $91.13 | $46K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 415 | 39 | $0.51 | $213 |
| 99233 Hospital E&M - Subsequent | Facility | 332 | 64 | $91.66 | $30K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 198 | 15 | $0.22 | $43.51 |
| 96367 Intravenous Infusion, Hydration | Office | 173 | 23 | $21.79 | $3,771 |
| 96372 Injection Administration | Office | 158 | 14 | $11.24 | $1,775 |
| 84443 Clinical Chemistry | Office | 144 | 107 | $16.46 | $2,370 |
| 82728 Clinical Chemistry | Office | 136 | 67 | $13.36 | $1,817 |
| 96413 Chemotherapy Administration | Office | 132 | 17 | $98.72 | $13K |
By year: 2022 $1.4M for 177,916 services; 2023 $845K for 136,230 services; 2024 $610K for 98,701 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,241 | 439 | $7.60 | $9,436 |
| 36415 Venipuncture Blood Collection | 1,145 | 427 | $8.65 | $9,904 |
| 80053 Clinical Chemistry | 788 | 382 | $10.34 | $8,147 |
| 84443 Clinical Chemistry | 144 | 107 | $16.46 | $2,370 |
| 82728 Clinical Chemistry | 136 | 67 | $13.36 | $1,817 |
| 82378 Clinical Chemistry | 106 | 71 | $18.58 | $1,969 |
| 85610 Clinical Chemistry | 92 | 20 | $4.16 | $383 |
| 84153 Clinical Chemistry | 47 | 22 | $18.02 | $847 |
| 85651 Clinical Chemistry | 41 | 35 | $4.18 | $171 |
Medicare prescription drug claims, 2024
In 2024, the drug Mary Milam prescribed most often to Medicare patients was Levothyroxine Sodium, with 169 prescriptions and refills. In total Mary Milam wrote 1,644 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 169 | 485 | 55 | $1,722 |
| Eliquis Apixaban | 77 | 159 | 21 | $93K |
| Allopurinol Generic | 67 | 166 | 22 | $553 |
| Ondansetron Hcl Generic | 58 | 58 | 29 | $433 |
| Warfarin Sodium Generic | 55 | 148 | 13 | $744 |
| Megestrol Acetate Generic | 54 | 60 | 14 | $2,418 |
| Xarelto Rivaroxaban | 47 | 79 | Under 11 | $43K |
| Gabapentin Generic | 42 | 98 | 16 | $812 |
| Folic Acid Generic | 37 | 110 | Under 11 | $720 |
| Pantoprazole Sodium Generic | 34 | 96 | 13 | $284 |
| Imbruvica Ibrutinib | 32 | 32 | Under 11 | $461K |
| Revlimid Lenalidomide | 31 | 31 | Under 11 | $508K |
| Letrozole Generic | 29 | 87 | Under 11 | $919 |
| Anastrozole Generic | 29 | 85 | Under 11 | $498 |
| Amlodipine Besylate Generic | 27 | 79 | Under 11 | $138 |
Brand drugs: - claims; generic drugs: 1,233 claims; opioid claims: 60.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mary Milam $3,403 ($3,403 in general payments such as food, travel and fees) from 42 companies. The largest payer was Celgene Corporation with $276.
| Company | Payments | Amount |
|---|---|---|
| Celgene Corporation BMY | 11 | $276 |
| Pfizer Inc. PFE | 14 | $273 |
| E.R. Squibb & Sons, L.L.C. BMY | 9 | $186 |
| TerSera Therapeutics LLC | 6 | $163 |
| Incyte Corporation INCY | 14 | $150 |
| PharmaEssentia USA Corporation 6446.TW | 5 | $148 |
| Sobi, Inc SOBI.ST | 3 | $136 |
| Gilead Sciences, Inc. GILD | 6 | $117 |
| Janssen Biotech, Inc. JNJ | 5 | $117 |
| Lilly USA, LLC LLY | 4 | $109 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.